Literature DB >> 2548964

Comparison of erythromycin ethylsuccinate and co-trimoxazole for treatment of pertussis.

J E Hoppe1, U Halm, H J Hagedorn, A Kraminer-Hagedorn.   

Abstract

Fifty-five ambulatory children with early culture-proven pertussis were treated for two weeks either with erythromycin ethylsuccinate (n = 28) (50-80 mg/kg/day in three doses during meals) or with co-trimoxazole (n = 27) (6-10 mg trimethoprim/kg/day in two doses after meals). After completion of treatment, all patients in the erythromycin group were culture-negative, while in the co-trimoxazole group one child was still culture-positive. In this case vomiting may have played a role. Both agents appear to be able to eradicate Bordetella pertussis from the nasopharynx of patients with early whooping cough.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2548964     DOI: 10.1007/BF01639525

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  26 in total

Review 1.  Treatment and prevention of pertussis by antimicrobial agents (Part II).

Authors:  J E Hoppe; A Haug
Journal:  Infection       Date:  1988 May-Jun       Impact factor: 3.553

2.  Trimethoprim-sulphamethoxazole in pertussis: comparison with tetracycline.

Authors:  K J Adcock; S Reddy; O A Okubadejo; D Montefiore
Journal:  Arch Dis Child       Date:  1972-04       Impact factor: 3.791

3.  A simple chemically defined medium for the production of phase I Bordetella pertussis.

Authors:  D W Stainer; M J Scholte
Journal:  J Gen Microbiol       Date:  1970-10

Review 4.  Antimicrobial susceptibility of Bordetella pertussis (Part I).

Authors:  J E Hoppe; A Haug
Journal:  Infection       Date:  1988 Mar-Apr       Impact factor: 3.553

5.  Erythromycin for treatment and prevention of pertussis.

Authors:  J W Bass
Journal:  Pediatr Infect Dis       Date:  1986 Jan-Feb

6.  Whooping cough--aspects of pathogenesis and treatment.

Authors:  B Trollfors
Journal:  Acta Otolaryngol Suppl       Date:  1984

7.  Antibiotic susceptibility testing of Bordetella pertussis.

Authors:  L H Field; C D Parker
Journal:  Am J Clin Pathol       Date:  1980-09       Impact factor: 2.493

Review 8.  Trimethoprim-sulfamethoxazole: an assessment of more than 12 years of use.

Authors:  A J Salter
Journal:  Rev Infect Dis       Date:  1982 Mar-Apr

9.  Levels of erythromycin in pulmonary tissue and bronchial mucus compared to those of amoxycillin.

Authors:  Y Brun; F Forey; J P Gamondes; A Tebib; J Brune; J Fleurette
Journal:  J Antimicrob Chemother       Date:  1981-12       Impact factor: 5.790

10.  Erythromycin in the treatment of pertussis: a study of bacteriologic and clinical effects.

Authors:  S O Bergquist; S Bernander; H Dahnsjö; B Sundelöf
Journal:  Pediatr Infect Dis J       Date:  1987-05       Impact factor: 2.129

View more
  8 in total

Review 1.  State of art in antibacterial susceptibility of Bordetella pertussis and antibiotic treatment of pertussis.

Authors:  J E Hoppe
Journal:  Infection       Date:  1998 Jul-Aug       Impact factor: 3.553

2.  Update of epidemiology, diagnosis, and treatment of pertussis.

Authors:  J E Hoppe
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-03       Impact factor: 3.267

Review 3.  Rational prescribing of antibacterials in ambulatory children.

Authors:  J E Hoppe
Journal:  Pharmacoeconomics       Date:  1996-12       Impact factor: 4.981

4.  Identification of a mutation associated with erythromycin resistance in Bordetella pertussis: implications for surveillance of antimicrobial resistance.

Authors:  J M Bartkus; B A Juni; K Ehresmann; C A Miller; G N Sanden; P K Cassiday; M Saubolle; B Lee; J Long; A R Harrison; J M Besser
Journal:  J Clin Microbiol       Date:  2003-03       Impact factor: 5.948

Review 5.  Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies.

Authors:  Seema Mattoo; James D Cherry
Journal:  Clin Microbiol Rev       Date:  2005-04       Impact factor: 26.132

6.  The First Macrolide-Resistant Bordetella pertussis Strains Isolated From Iranian Patients.

Authors:  Fereshteh Shahcheraghi; Masoumeh Nakhost Lotfi; Vajiheh Sadat Nikbin; Fahimeh Shooraj; Reza Azizian; Masoumeh Parzadeh; Mohammad Reza Allahyar Torkaman; Seyed Mohsen Zahraei
Journal:  Jundishapur J Microbiol       Date:  2014-06-01       Impact factor: 0.747

7.  Neurologic alterations in an HIV adult patient with pertussis: a case report.

Authors:  María Camila Arango-Granados; Iván Mauricio Trompa
Journal:  BMC Infect Dis       Date:  2020-07-02       Impact factor: 3.090

Review 8.  Emerging macrolide resistance in Bordetella pertussis in mainland China: Findings and warning from the global pertussis initiative.

Authors:  Ye Feng; Cheng-Hsun Chiu; Ulrich Heininger; Daniela Flavia Hozbor; Tina Quanbee Tan; Carl-Heinz Wirsing von König
Journal:  Lancet Reg Health West Pac       Date:  2021-02-05
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.